文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

新型肺超声方案评估COVID-19肺炎肺损伤范围的可行性

Feasibility of a New Lung Ultrasound Protocol to Determine the Extent of Lung Injury in COVID-19 Pneumonia.
PubMed 文献 · Chest · 2022-07-31
一句话结论在急诊COVID-19肺炎患者中,LUSext与CT容积测量的病变严重程度正相关(R=0.67),与PaO2/FiO2比值负相关,操作耗时5±1.5分钟。

该观察性研究在急诊纳入179例确诊COVID-19且床旁肺超声和CT均显示肺炎的患者,采用视觉量化肺表面典型COVID-19肺炎征象扩展百分比的新方案LUSext,并与专门软件回顾性计算的CT容积测量(CTvol)及PaO2/FiO2比值进行相关性分析。结果显示LUSext可行性100%,操作时间5±1.5分钟,LUSext与CTvol正相关(R=0.67;P<.0001),LUSext与CTvol均与PaO2/FiO2比值负相关(分别为R=-0.66和R=-0.54;P<.0001)。作者认为LUSext是评估CoARDS肺炎严重程度的实用、简便床旁指标,其临床和预后影响需进一步研究。

要点

  • 在急诊确诊COVID-19且床旁肺超声和CT均显示肺炎的患者中,LUSext可行性为100%,操作时间5±1.5分钟。
  • LUSext与CTvol正相关(R=0.67;P<.0001),提示LUSext可反映CT所测病变范围。
  • LUSext与PaO2/FiO2比值负相关(R=-0.66;P<.0001),CTvol与PaO2/FiO2比值负相关(R=-0.54;P<.0001)。
  • 作者认为LUSext是评估CoARDS肺炎严重程度的实用、简便床旁指标,其临床和预后影响需进一步研究。

适用人群与场景

  • 急诊科确诊COVID-19、床旁肺超声和CT扫描均显示肺炎的患者,为便利抽样人群。

研究设计与关键结果

  • 观察性研究,纳入179例急诊确诊COVID-19且床旁肺超声和CT均显示肺炎的患者。
  • LUSext通过视觉量化肺表面典型COVID-19肺炎征象的扩展百分比。
  • 所有CT扫描研究均由专门设计的软件回顾性分析以计算CTvol。
  • LUSext可行性为100%,操作LUS扫描时间为5±1.5分钟。
  • LUSext与CTvol呈正相关(R=0.67;P<.0001)。
  • LUSext与PaO2/FiO2比值呈负相关(R=-0.66;P<.0001),CTvol与PaO2/FiO2比值呈负相关(R=-0.54;P<.0001)。

证据类型、等级与局限

  • 证据类型:观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为LUSext是评估CoARDS肺炎严重程度的实用、简便床旁指标,其临床和预后影响需进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Lung ultrasound (LUS) scanning is useful to diagnose and assess the severity of pulmonary lesions during COVID-19-related ARDS (CoARDS). A conventional LUS score is proposed to measure the loss of aeration during CoARDS. However, this score was validated during the pre-COVID-19 era in patients with ARDS in the ICU and does not consider the differences with CoARDS. An alternative LUS method is based on grading the percentage of extension of the typical signs of COVID-19 pneumonia on the lung surface (LUSext).

RESEARCH QUESTION: Is LUSext feasible in patients with COVID-19 at the onset of disease, and does it correlate with the volumetric measure of severity of COVID-19 pneumonia lesions at CT scan (CTvol)?

STUDY DESIGN AND METHODS: This observational study enrolled a convenience sampling of patients in the ED with confirmed COVID-19 whose condition demonstrated pneumonia at bedside LUS and CT scan. LUSext was visually quantified. All CT scan studies were analyzed retrospectively by a specifically designed software to calculate the CTvol. The correlation between LUSext and CTvol, and the correlations of each score with Pao2/Fio2 ratio were calculated.

RESULTS: We analyzed data from 179 patients. Feasibility of LUSext was 100%. Time to perform LUS scan was 5 ± 1.5 mins. LUSext and CTvol were correlated positively (R = 0.67; P < .0001). Both LUSext and CTvol showed negative correlation with Pao2/Fio2 ratio (R = -0.66 and R = -0.54; P < .0001, respectively).

INTERPRETATION: LUSext is a valid measure of the severity of the lesions when compared with the CT scan. Not only are LUSext and CTvol correlated, but they also have similar inverse correlation with the severity of respiratory failure. LUSext is a practical and simple bedside measure of the severity of pneumonia in CoARDS, whose clinical and prognostic impact need to be investigated further.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Volpicelli G, Fraccalini T, Cardinale L, et al. Feasibility of a New Lung Ultrasound Protocol to Determine the Extent of Lung Injury in COVID-19 Pneumonia. Chest. 2022. PMID: 35921882. doi:10.1016/j.chest.2022.07.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。